Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A practical guide for mutational signature analysis in hematological malignancies

  • Maura, Francesco
  • Degasperi, Andrea
  • Nadeu, Ferran
  • Leongamornlert, Daniel
  • Davies, Helen
  • Moore, Luiza
  • Royo, Romina
  • Ziccheddu, Bachisio
  • Puente, Xosé S.
  • Avet-Loiseau, Herve
  • Campbell, Peter J.
  • Nik Zainal, Serena
  • Campo, Elias
  • Munshi, Nikhil
  • Bolli, Niccolò
Analysis of mutational signatures is becoming routine in cancer genomics, with implications for pathogenesis, classification, prognosis, and even treatment decisions. However, the field lacks a consensus on analysis and result interpretation. Using whole-genome sequencing of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia, we compare the performance of public signature analysis tools. We describe caveats and pitfalls of de novo signature extraction and fitting approaches, reporting on common inaccuracies: erroneous signature assignment, identification of localized hyper-mutational processes, overcalling of signatures. We provide reproducible solutions to solve these issues and use orthogonal approaches to validate our results. We show how a comprehensive mutational signature analysis may provide relevant biological insights, reporting evidence of c-AID activity among unmutated CLL cases or the absence of BRCA1/BRCA2-mediated homologous recombination deficiency in a MM cohort. Finally, we propose a general analysis framework to ensure production of accurate and reproducible mutational signature data., F.M. is supported by A.I.L. (Associazione Italiana Contro le Leucemie-Linfomi e Mieloma ONLUS), by S.I.E.S. (Società Italiana di Ematologia Sperimentale) and by the Memorial Sloan Kettering Cancer Center NCI Core Grant (P30 CA 008748). N.B. is funded by the University of Milan (project 22597-PSR2017_DIP_032) and by the European Research Council under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 817997). X.S.P. is supported by thr Ministerio de Economía y Competitividad Grant No. SAF2017–87811-R. F.N. is supported by a pre-doctoral fellowship of the MINECO (BES-2016–076372). This work was supported by the Instituto de Salud Carlos III (project PMP15/00007, F.N., E.C.), the “la Caixa” Foundation Grant No HR17-00221 (Health Research 2017 Program, F.N., E.C.), the Ministerio de Economía y Competitividad (MINECO) SAF2013-45836-R (E.C.) from. Plan Nacional de I + D + I, Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-1142 (E.C.) and the European Regional Development Fund “Una manera de hacer Europa”. E.C. is supported by ICREA under the ICREA Academia program. A.D. is funded by a CRUK Pioneer Award C60100/A23433. S.N.Z. is funded by a CRUK Advanced Clinician Scientist Award (C60100/A23916) and a CRUK Grand Challenge Award (C60100/A25274). This work was supported by: Department of Veterans Affairs Merit Review Award I01BX001584-01 (N.C.M.), NIH grants P01-155258 (N.C.M., H.A.L., M.F., P.J.C., K.C.A.) and 5P50CA100707-13 (N.C.M., H.A.L., K.C.A). We thank Michael R. Stratton for discussions and help in data interpretation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Germline mutations in FAN1 cause hereditary colorectal cancer by impairing DNA repair

  • Seguí, Nuria
  • Mina, Leonardo B.
  • Durán, Mercedes
  • Lastra, Enrique
  • Blanco, Ignacio
  • Valle, Laura
Under a Creative Commons license.-- et al., Identification of genes associated with hereditary cancers facilitates management of patients with family histories of cancer. We performed exome sequencing of DNA from 3 individuals from a family with colorectal cancer who met the Amsterdam criteria for risk of hereditary nonpolyposis colorectal cancer. These individuals had mismatch repair-proficient tumors and each carried nonsense variant in the FANCD2/FANCI-associated nuclease 1 gene (FAN1), which encodes a nuclease involved in DNA inter-strand cross-link repair. We sequenced FAN1 in 176 additional families with histories of colorectal cancer and performed in vitro functional analyses of the mutant forms of FAN1 identified. We detected FAN1 mutations in approximately 3% of families who met the Amsterdam criteria and had mismatch repair-proficient cancers with no previously associated mutations. These findings link colorectal cancer predisposition to the Fanconi anemia DNA repair pathway, supporting the connection between genome integrity and cancer risk., This work was funded by the Spanish Ministry of Economy and Competitiveness (SAF2012-38885 [LV], SAF2012-31881 [JS], SAF2013-45836R [XSP] and SAF2012-33636 [GC] and Ramón y Cajal Contract to LV); the Carlos III Health Institute (PI11-01439 [VM], PI13/00285 [CL] and fellowship to NS); CIBERESP (CB07/02/2005 [VM]); RTICC (RD12/0036/0031, RD12/0036/0006, RD12/0036/0008 and RD12/0036/0067); the EU FP7 project ASSET (grant agreement 259348 to AV); L’Oréal-UNESCO “For Women in Science”; the Scientific Foundation Asociación Española Contra el Cáncer; and the Government of Catalonia (2014SGR338 [GC] and 2009SGR0489 [JS]). JS is also funded by ICREA Academia and the European Regional Development FEDER Funds. CIBERER is an initiative of the Carlos III Health Institute., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández, Gonzalo
  • Ramírez, María José
  • Minguillón, Jordi
  • Quiles, Paco
  • Ruiz de Garibay, Gorka
  • Aza Carmona, Miriam
  • Bogliolo, Massimo
  • Pujol, Roser
  • Prados-Carvajal, Rosario
  • Fernández, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara
  • Díez, Orland
  • Benitez, Javier
  • Salinas, Mónica
  • Teulé, Alex
  • Brunet, Joan
  • Radice, Paolo
  • Peterlongo, Paolo
  • Schindler, Detlev
  • Huertas Sánchez, Pablo
  • Puente, Xose S.
  • Lázaro, Conxi
  • Pujana, Miguel Ángel
  • Surrallés, Jordi
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand crosslinking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency, Surrallés laboratory is supported by the ICREA-Academia program, the Marató de TV3 (project 464/C/2012), the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023, SAF2012-31881, SAF2013-45836-R and SAF2015-64152-R), the European Commission (EUROFANCOLEN project HEALTH-F5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc., and the “Fondo Europeo de Desarrollo Regional, una manera de hacer Europa” (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain. This work was also supported by grants from the Asociación Española Contra el Cáncer (AECC, Hereditary Cancer group, 2010), the Generalitat de Catalunya (SGR 2014-364 and 2014-338), and the Instituto de Salud Carlos III (PIE13/00022-ONCOPROFILE, CP10/00617, PI10/01422, PI12/02585, PI13/00285, PI15/00854, PI16/00563, PI16/01218, and RTICC RD12/0036/0008). S.G.-E. is funded by a Miguel Servet contract from the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Association between germline mutations in BRF1, a subunit of the RNA polymerase III transcription complex, and hereditary colorectal cancer

  • Bellido, Fernando
  • Sowada, Nadine
  • Mur, Pilar
  • Lázaro, Conxi
  • Pons, Tirso
  • Valdés-Mas, Rafael
  • Pineda, Marta
  • Aiza, Gemma
  • Iglesias, Silvia
  • Soto, José Luis
  • Urioste, Miguel
  • Caldés, Trinidad
  • Balbín, Milagros
  • Blay, Pilar
  • Rueda, Daniel
  • Durán, Mercedes
  • Valencia, Alfonso
  • Moreno, Victor
  • Brunet, Joan
  • Blanco, Ignacio
  • Navarro, Matilde
  • Calin, George G.
  • Borck, Guntram
  • Puente, Xose S.
  • Capellá, Gabriel
  • Valle, Laura
[Background & Aims] Although there is a genetic predisposition to colorectal cancer (CRC), few of the genes that affect risk have been identified. We performed whole-exome sequence analysis of individuals in a high-risk family without mutations in genes previously associated with CRC risk to identify variants associated with inherited CRC., [Methods] We collected blood samples from 3 relatives with CRC in Spain (65, 62, and 40 years old at diagnosis) and performed whole-exome sequence analyses. Rare missense, truncating or splice-site variants shared by the 3 relatives were selected. We used targeted pooled DNA amplification followed by next generation sequencing to screen for mutations in candidate genes in 547 additional hereditary and/or early-onset CRC cases (502 additional families). We carried out protein-dependent yeast growth assays and transfection studies in the HT29 human CRC cell line to test the effects of the identified variants., [Results] A total of 42 unique or rare (population minor allele frequency below 1%) nonsynonymous genetic variants in 38 genes were shared by all 3 relatives. We selected the BRF1 gene, which encodes an RNA polymerase III transcription initiation factor subunit for further analysis, based on the predicted effect of the identified variant and previous association of BRF1 with cancer. Previously unreported or rare germline variants in BRF1 were identified in 11 of 503 CRC families, a significantly greater proportion than in the control population (34 of 4300). Seven of the identified variants (1 detected in 2 families) affected BRF1 mRNA splicing, protein stability, or expression and/or function., [Conclusions] In an analysis of families with a history of CRC, we associated germline mutations in BRF1 with predisposition to CRC. We associated deleterious BRF1 variants with 1.4% of familial CRC cases, in individuals without mutations in high-penetrance genes previously associated with CRC. Our findings add additional evidence to the link between defects in genes that regulate ribosome synthesis and risk of CRC., This work was funded by the Spanish Ministry of Economy and Competitiveness, co-funded by FEDER funds—a way to build Europe (SAF2016–80888-R [LV], SAF2013–45836-R [XSP], SAF2015–68016-R [GC and MP], and Juan de la Cierva contract [PM]); Carlos III National Health Institute (PI16/00563 [CL], PI11/01439 [VM], PI14/00459 [MU], and CIBERONC); Government of Catalonia (2014SGR338, 2014SGR647); Catalan Department of Health (PERIS); the EU FP7 project ASSET (grant agreement 259348 [AV]); Joint BSC-IRB-CRG Program in Computational Biology; Severo Ochoa Award (SEV 2015-0493 [AV]) and Scientific Foundation Asociación Española Contra el Cáncer., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A practical guide for mutational signature analysis in hematological malignancies

  • Maura, Francesco
  • Degasperi, Andrea
  • Nadeu, Ferran
  • Leongamornlert, Daniel
  • Davies, Helen
  • Moore, Luiza
  • Royo, Romina
  • Ziccheddu, Bachisio
  • Puente, Xosé S.
  • Avet-Loiseau, Herve
  • Campbell, Peter J.
  • Nik Zainal, Serena
  • Campo, Elias
  • Munshi, Nikhil
  • Bolli, Niccolò
Analysis of mutational signatures is becoming routine in cancer genomics, with implications for pathogenesis, classification, prognosis, and even treatment decisions. However, the field lacks a consensus on analysis and result interpretation. Using whole-genome sequencing of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia, we compare the performance of public signature analysis tools. We describe caveats and pitfalls of de novo signature extraction and fitting approaches, reporting on common inaccuracies: erroneous signature assignment, identification of localized hyper-mutational processes, overcalling of signatures. We provide reproducible solutions to solve these issues and use orthogonal approaches to validate our results. We show how a comprehensive mutational signature analysis may provide relevant biological insights, reporting evidence of c-AID activity among unmutated CLL cases or the absence of BRCA1/BRCA2-mediated homologous recombination deficiency in a MM cohort. Finally, we propose a general analysis framework to ensure production of accurate and reproducible mutational signature data., F.M. is supported by A.I.L. (Associazione Italiana Contro le Leucemie-Linfomi e Mieloma ONLUS), by S.I.E.S. (Società Italiana di Ematologia Sperimentale) and by the Memorial Sloan Kettering Cancer Center NCI Core Grant (P30 CA 008748). N.B. is funded by the University of Milan (project 22597-PSR2017_DIP_032) and by the European Research Council under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 817997). X.S.P. is supported by thr Ministerio de Economía y Competitividad Grant No. SAF2017–87811-R. F.N. is supported by a pre-doctoral fellowship of the MINECO (BES-2016–076372). This work was supported by the Instituto de Salud Carlos III (project PMP15/00007, F.N., E.C.), the “la Caixa” Foundation Grant No HR17-00221 (Health Research 2017 Program, F.N., E.C.), the Ministerio de Economía y Competitividad (MINECO) SAF2013-45836-R (E.C.) from. Plan Nacional de I + D + I, Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-1142 (E.C.) and the European Regional Development Fund “Una manera de hacer Europa”. E.C. is supported by ICREA under the ICREA Academia program. A.D. is funded by a CRUK Pioneer Award C60100/A23433. S.N.Z. is funded by a CRUK Advanced Clinician Scientist Award (C60100/A23916) and a CRUK Grand Challenge Award (C60100/A25274). This work was supported by: Department of Veterans Affairs Merit Review Award I01BX001584-01 (N.C.M.), NIH grants P01-155258 (N.C.M., H.A.L., M.F., P.J.C., K.C.A.) and 5P50CA100707-13 (N.C.M., H.A.L., K.C.A). We thank Michael R. Stratton for discussions and help in data interpretation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma

  • Escudero Monreal, Laura
  • Llort Sales, Anna
  • Arias Piñeiro, Alexandra
  • Diaz-Navarro, Ander
  • Martínez Ricarte, Francisco Ramón
  • Rubio Pérez, Carlota
  • Mayor Ferreras, Regina Gabriela
  • Caratú, Ginevra
  • Martinez Saez, Elena Antima
  • Vázquez Méndez, Josefa Élida
  • Hladun Alvaro, Raquel
  • Gros Subias, Luís
  • Ramon y Cajal Agüeras, Santiago
  • Poca Pastor, Ma Antonia
  • Sahuquillo Barris, Joan
  • Gallego Melcón, Soledad
  • Seoane Suarez, Joan
Genètica del càncer; Càncer del SNC; Càncer pediàtric, Genética del cáncer; Cáncer del SNC; Cáncer pediátrico, Cancer genetics; CNS cancer; Paediatric cancer, The molecular characterisation of medulloblastoma, the most common paediatric brain tumour, is crucial for the correct management and treatment of this heterogenous disease. However, insufficient tissue sample, the presence of tumour heterogeneity, or disseminated disease can challenge its diagnosis and monitoring. Here, we report that the cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) recapitulates the genomic alterations of the tumour and facilitates subgrouping and risk stratification, providing valuable information about diagnosis and prognosis. CSF ctDNA also characterises the intra-tumour genomic heterogeneity identifying small subclones. ctDNA is abundant in the CSF but barely present in plasma and longitudinal analysis of CSF ctDNA allows the study of minimal residual disease, genomic evolution and the characterisation of tumours at recurrence. Ultimately, CSF ctDNA analysis could facilitate the clinical management of medulloblastoma patients and help the design of tailored therapeutic strategies, increasing treatment efficacy while reducing excessive treatment to prevent long-term secondary effects., We would like to thank the patients at the Vall d’Hebron Hospital that were enrolled in the study and their families. The study was undertaken with the support of the Fundación Asociación Española contra el Cáncer (AECC), FERO (EDM), Ramón Areces Foundation, Cellex Foundation, BBVA (CAIMI), the ISCIII, FIS (PI16/01278) and the Juan de la Cierva fellowship (L.E). X.S.P. is supported by Ministerio de Economía y Competitividad (MINECO) SAF2013-45836-R and CIBERONC; A.D.N. is supported by the Department of Education of the Basque Government (grant number PRE_2017_1_0100). We thank CERCA Programme/Generalitat de Catalunya for institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández, Gonzalo
  • Ramírez, María José
  • Minguillón, Jordi
  • Quiles, Paco
  • Ruiz de Garibay, Gorka
  • Aza-Carmona, Miriam
  • Bogliolo, Massimo
  • Pujol, Roser
  • Prados-Carvajal, Rosario
  • Fernández, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara
  • Diez, Orland
  • Benítez, Javier
  • Salinas, Mónica
  • Teulé, Alex
  • Brunet, Joan
  • Radice, Paolo
  • Peterlongo, Paolo
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose S.
  • Lázaro, Conxi
  • Pujana, Miquel Àngel
  • Surrallés, Jordi
We thank Dr. Andre Nussenzweig and Dr. Elsa Callen for critical reading of the manuscript and helpful comments and Dr. Joaquin Dopazo for his help with the CIBERER Spanish Variant Server. Surrallés laboratory is supported by the ICREAAcademia program, the Marató de TV3 (project 464/C/2012), the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023, SAF2012-31881, SAF2013-45836-R and SAF2015-64152-R), the European Commission (EUROFANCOLEN project HEALTHF5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc., and the “Fondo Europeo de Desarrollo Regional, una manera de hacer Europa” (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain. This work was also supported by grants from the Asociación Española Contra el Cáncer (AECC, Hereditary Cancer group, 2010), the Generalitat de Catalunya (SGR 2014-364 and 2014-338), and the Instituto de Salud Carlos III (PIE13/00022-ONCOPROFILE, CP10/00617, PI10/01422, PI12/02585, PI13/00285, PI15/00854, PI16/00563, PI16/01218, and RTICC RD12/0036/0008). S.G.-E. is funded by a Miguel Servet contract from the Instituto de Salud Carlos III., BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine

  • Castellsagué, Joan|||0000-0002-2579-3137
  • Gel, Bernat|||0000-0001-8878-349X
  • Fernández-Rodríguez, Juana
  • Llatjós, Roger
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Pérez-Sidelnikova, Diana
  • Garcia del Muro, Xavier|||0000-0001-5571-2847
  • Viñals, Joan Maria
  • Vidal, August|||0000-0001-5727-2099
  • Valdés-Mas, Rafael
  • Terribas, Ernest
  • López-Doriga, Adriana
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Capella, Gabriel|||0000-0002-4669-7320
  • Puente, Xose S.|||0000-0001-9525-1483
  • Serra, Eduard|||0000-0003-2895-9857
  • Villanueva Garatachea, Alberto
  • Lázaro García, Conxi|||0000-0002-7198-5906
Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas that can arise either sporadically or in association with neurofibromatosis type 1 (NF1). These aggressive malignancies confer poor survival, with no effective therapy available. We present the generation and characterization of five distinct MPNST orthoxenograft models for preclinical testing and personalized medicine. Four of the models are patient-derived tumor xenografts (PDTX), two independent MPNSTs from the same NF1 patient and two from different sporadic patients. The fifth model is an orthoxenograft derived from an NF1-related MPNST cell line. All MPNST orthoxenografts were generated by tumor implantation, or cell line injection, next to the sciatic nerve of nude mice, and were perpetuated by 7-10 mouse-to-mouse passages. The models reliably recapitulate the histopathological properties of their parental primary tumors. They also mimic distal dissemination properties in mice. Human stroma was rapidly lost after MPNST engraftment and replaced by murine stroma, which facilitated genomic tumor characterization. Compatible with an origin in a catastrophic event and subsequent genome stabilization, MPNST contained highly altered genomes that remained remarkably stable in orthoxenograft establishment and along passages. Mutational frequency and type of somatic point mutations were highly variable among the different MPNSTs modeled, but very consistent when comparing primary tumors with matched orthoxenografts generated. Unsupervised cluster analysis and principal component analysis (PCA) using an MPNST expression signature of ~1,000 genes grouped together all primary tumor-orthoxenograft pairs. Our work points to differences in the engraftment process of primary tumors compared with the engraftment of established cell lines. Following standardization and extensive characterization and validation, the orthoxenograft models were used for initial preclinical drug testing. Sorafenib (a BRAF inhibitor), in combination with doxorubicin or rapamycin, was found to be the most effective treatment for reducing MPNST growth. The development of genomically well-characterized preclinical models for MPNST allowed the evaluation of novel therapeutic strategies for personalized medicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Quiles, Francisco
  • Ruiz de Garibay, G.
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Prados-Carvajal, Rosario
  • Fernández-Rodríguez, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Diez, Orland|||0000-0001-7339-0570
  • Benitez, Javier|||0000-0002-0923-7202
  • Salinas, Monica
  • Teule, Alex|||0000-0003-0028-7200
  • Brunet, Joan|||0000-0003-1945-3512
  • Radice, Paolo|||0000-0001-6298-4111
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose P.
  • Lázaro, Coxi
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma

  • Escudero, Laura|||0000-0001-7385-673X
  • Llort, Anna|||0000-0001-9741-1655
  • Arias, Alexandra
  • Diaz-Navarro, Ander|||0000-0001-6808-4800
  • Martinez-Ricarte, Fran|||0000-0003-4567-0828
  • Rubio-Perez, Carlota|||0000-0002-1921-168X
  • Mayor, Regina
  • Caratù, Ginevra|||0000-0003-1085-8062
  • Martinez-Saez, Elena|||0000-0001-6004-5364
  • Vázquez-Méndez, Élida
  • Lesende-Rodríguez, Iván
  • Hladun, Raquel|||0000-0002-3191-1750
  • Gros, Luis
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Poca Pastor, María Antonia|||0000-0002-3831-0536
  • Puente, Xose S.|||0000-0001-9525-1483
  • Sahuquillo Barris, Juan|||0000-0003-0713-5875
  • Gallego, Soledad|||0000-0002-4712-9624
  • Seoane Suárez, Joan|||0000-0002-6541-5974
The molecular characterisation of medulloblastoma, the most common paediatric brain tumour, is crucial for the correct management and treatment of this heterogenous disease. However, insufficient tissue sample, the presence of tumour heterogeneity, or disseminated disease can challenge its diagnosis and monitoring. Here, we report that the cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) recapitulates the genomic alterations of the tumour and facilitates subgrouping and risk stratification, providing valuable information about diagnosis and prognosis. CSF ctDNA also characterises the intra-tumour genomic heterogeneity identifying small subclones. ctDNA is abundant in the CSF but barely present in plasma and longitudinal analysis of CSF ctDNA allows the study of minimal residual disease, genomic evolution and the characterisation of tumours at recurrence. Ultimately, CSF ctDNA analysis could facilitate the clinical management of medulloblastoma patients and help the design of tailored therapeutic strategies, increasing treatment efficacy while reducing excessive treatment to prevent long-term secondary effects. Non-invasive and precise methods are critical for monitoring paediatric brain cancers. Here the authors show that the molecular alterations and heterogeneity of paediatric medulloblastomas can be reliably detected in circulating tumour DNA from the cerebrospinal fluid - a routinely collected sample
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma

  • Escudero Monreal, Laura
  • Llort Sales, Anna
  • Arias Piñeiro, Alexandra
  • Diaz-Navarro, Ander
  • Martínez Ricarte, Francisco Ramón
  • Rubio Pérez, Carlota
  • Mayor Ferreras, Regina Gabriela
  • Caratú, Ginevra
  • Martinez Saez, Elena Antima
  • Vázquez Méndez, Josefa Élida
  • Hladun Alvaro, Raquel
  • Gros Subias, Luís
  • Ramon y Cajal Agüeras, Santiago
  • Poca Pastor, Ma Antonia
  • Sahuquillo Barris, Joan
  • Gallego Melcón, Soledad
  • Seoane Suarez, Joan
Genètica del càncer; Càncer del SNC; Càncer pediàtric, Genética del cáncer; Cáncer del SNC; Cáncer pediátrico, Cancer genetics; CNS cancer; Paediatric cancer, The molecular characterisation of medulloblastoma, the most common paediatric brain tumour, is crucial for the correct management and treatment of this heterogenous disease. However, insufficient tissue sample, the presence of tumour heterogeneity, or disseminated disease can challenge its diagnosis and monitoring. Here, we report that the cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) recapitulates the genomic alterations of the tumour and facilitates subgrouping and risk stratification, providing valuable information about diagnosis and prognosis. CSF ctDNA also characterises the intra-tumour genomic heterogeneity identifying small subclones. ctDNA is abundant in the CSF but barely present in plasma and longitudinal analysis of CSF ctDNA allows the study of minimal residual disease, genomic evolution and the characterisation of tumours at recurrence. Ultimately, CSF ctDNA analysis could facilitate the clinical management of medulloblastoma patients and help the design of tailored therapeutic strategies, increasing treatment efficacy while reducing excessive treatment to prevent long-term secondary effects., We would like to thank the patients at the Vall d’Hebron Hospital that were enrolled in the study and their families. The study was undertaken with the support of the Fundación Asociación Española contra el Cáncer (AECC), FERO (EDM), Ramón Areces Foundation, Cellex Foundation, BBVA (CAIMI), the ISCIII, FIS (PI16/01278) and the Juan de la Cierva fellowship (L.E). X.S.P. is supported by Ministerio de Economía y Competitividad (MINECO) SAF2013-45836-R and CIBERONC; A.D.N. is supported by the Department of Education of the Basque Government (grant number PRE_2017_1_0100). We thank CERCA Programme/Generalitat de Catalunya for institutional support.